LEADER 01718nam  2200445   450 
001 9910711563903321
005 20190307141534.0
035   $a(CKB)5470000002484411
035   $a(OCoLC)1060613993
035   $a(EXLCZ)995470000002484411
100   $a20181102d2018      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 14$aThe administration's FDA reforms and reduced biopharmaceutical drug prices /$fThe Council of Economic Advisers
210  1$a[Washington, D.C.] :$cExecutive Office of the President of the United States, Council of Economic Advisers,$d2018.
215   $a1 online resource (17 pages) $ccolor illustrations
300   $a"October 2018."
320   $aIncludes bibliographical references (pages 15-17).
517 3 $aAdministration's Food and Drug Administration reforms and reduced biopharmaceutical drug prices
606   $aDrugs$zUnited States$xCosts
606   $aDrug approval$zUnited States
606   $aGeneric drugs$xGovernment policy$zUnited States
606   $aDrug development$zUnited States
606   $aPharmaceutical industry$xDeregulation$zUnited States
606   $aCompetition$xGovernment policy$zUnited States
615  0$aDrugs$xCosts.
615  0$aDrug approval
615  0$aGeneric drugs$xGovernment policy
615  0$aDrug development
615  0$aPharmaceutical industry$xDeregulation
615  0$aCompetition$xGovernment policy
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910711563903321
996   $aThe administration's FDA reforms and reduced biopharmaceutical drug prices$93474058
997   $aUNINA